
Investors Target PROCEPT BioRobotics Over Alleged Revenue Inflation
Shareholders of PROCEPT BioRobotics face a potential recovery path following a class action lawsuit alleging the company misled investors through aggressive accounting practices. The litigation focuses on claims that the firm artificially inflated revenue figures by pulling sales forward, creating a significant inventory glut between 2024 and 2026.






















